Cargando…

Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy

BACKGROUND: Immune checkpoint inhibitors have been demonstrated to improve overall survival. Atypical patterns of response have been reported, including dissociated response (DR). We evaluated the prevalence of DR. PATIENTS AND METHODS: Patients had to have a baseline computed tomography (CT) scan a...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaflard, Pauline, Paoletti, Xavier, Servois, Vincent, Tresca, Patricia, Pons-Tostivint, Elvire, Sablin, Marie-Paule, Ricci, Francesco, Loirat, Delphine, Hescot, Ségolène, Torossian, Nouritza, Bello Roufai, Diana, Kamal, Maud, Borcoman, Edith, Le Tourneau, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602606/
https://www.ncbi.nlm.nih.gov/pubmed/34562258
http://dx.doi.org/10.1007/s40268-021-00362-3
_version_ 1784601608576827392
author Vaflard, Pauline
Paoletti, Xavier
Servois, Vincent
Tresca, Patricia
Pons-Tostivint, Elvire
Sablin, Marie-Paule
Ricci, Francesco
Loirat, Delphine
Hescot, Ségolène
Torossian, Nouritza
Bello Roufai, Diana
Kamal, Maud
Borcoman, Edith
Le Tourneau, Christophe
author_facet Vaflard, Pauline
Paoletti, Xavier
Servois, Vincent
Tresca, Patricia
Pons-Tostivint, Elvire
Sablin, Marie-Paule
Ricci, Francesco
Loirat, Delphine
Hescot, Ségolène
Torossian, Nouritza
Bello Roufai, Diana
Kamal, Maud
Borcoman, Edith
Le Tourneau, Christophe
author_sort Vaflard, Pauline
collection PubMed
description BACKGROUND: Immune checkpoint inhibitors have been demonstrated to improve overall survival. Atypical patterns of response have been reported, including dissociated response (DR). We evaluated the prevalence of DR. PATIENTS AND METHODS: Patients had to have a baseline computed tomography (CT) scan and at least one follow-up CT scan and two target lesions (TLs). Three types of DR were evaluated using RECIST1.1: DR1, defined as at least one progressive and one responding TL; DR2, defined as at least one progressive and one stable TL; and DR3, defined as at least one stable and one responding TL. RESULTS: A total of 1244 measurements of 272 TLs were performed in 100 patients. Forty-nine out of the 272 TLs (18%) had received old or recent radiotherapy, and 42 (15%) had been biopsied. An objective response was observed in 22 patients (22%) and on 52 TLs (19%). DR1 were observed in 8% of patients. At the tumor measurement level, the response rate was lower in the case of prior radiotherapy (29% vs 34%, p = 0.01) and higher in the case of prior biopsy (40% vs 32%, p = 0.02). CONCLUSIONS: A DR was observed in 8% of patients. Response rate was lower in the case of prior radiotherapy and higher in the case of prior biopsy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40268-021-00362-3.
format Online
Article
Text
id pubmed-8602606
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-86026062021-12-02 Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy Vaflard, Pauline Paoletti, Xavier Servois, Vincent Tresca, Patricia Pons-Tostivint, Elvire Sablin, Marie-Paule Ricci, Francesco Loirat, Delphine Hescot, Ségolène Torossian, Nouritza Bello Roufai, Diana Kamal, Maud Borcoman, Edith Le Tourneau, Christophe Drugs R D Original Research Article BACKGROUND: Immune checkpoint inhibitors have been demonstrated to improve overall survival. Atypical patterns of response have been reported, including dissociated response (DR). We evaluated the prevalence of DR. PATIENTS AND METHODS: Patients had to have a baseline computed tomography (CT) scan and at least one follow-up CT scan and two target lesions (TLs). Three types of DR were evaluated using RECIST1.1: DR1, defined as at least one progressive and one responding TL; DR2, defined as at least one progressive and one stable TL; and DR3, defined as at least one stable and one responding TL. RESULTS: A total of 1244 measurements of 272 TLs were performed in 100 patients. Forty-nine out of the 272 TLs (18%) had received old or recent radiotherapy, and 42 (15%) had been biopsied. An objective response was observed in 22 patients (22%) and on 52 TLs (19%). DR1 were observed in 8% of patients. At the tumor measurement level, the response rate was lower in the case of prior radiotherapy (29% vs 34%, p = 0.01) and higher in the case of prior biopsy (40% vs 32%, p = 0.02). CONCLUSIONS: A DR was observed in 8% of patients. Response rate was lower in the case of prior radiotherapy and higher in the case of prior biopsy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40268-021-00362-3. Springer International Publishing 2021-09-25 2021-12 /pmc/articles/PMC8602606/ /pubmed/34562258 http://dx.doi.org/10.1007/s40268-021-00362-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Vaflard, Pauline
Paoletti, Xavier
Servois, Vincent
Tresca, Patricia
Pons-Tostivint, Elvire
Sablin, Marie-Paule
Ricci, Francesco
Loirat, Delphine
Hescot, Ségolène
Torossian, Nouritza
Bello Roufai, Diana
Kamal, Maud
Borcoman, Edith
Le Tourneau, Christophe
Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy
title Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy
title_full Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy
title_fullStr Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy
title_full_unstemmed Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy
title_short Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy
title_sort dissociated responses in patients with metastatic solid tumors treated with immunotherapy
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602606/
https://www.ncbi.nlm.nih.gov/pubmed/34562258
http://dx.doi.org/10.1007/s40268-021-00362-3
work_keys_str_mv AT vaflardpauline dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy
AT paolettixavier dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy
AT servoisvincent dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy
AT trescapatricia dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy
AT ponstostivintelvire dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy
AT sablinmariepaule dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy
AT riccifrancesco dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy
AT loiratdelphine dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy
AT hescotsegolene dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy
AT torossiannouritza dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy
AT belloroufaidiana dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy
AT kamalmaud dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy
AT borcomanedith dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy
AT letourneauchristophe dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy